
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
You're a busy person with many things to do and little time to read. Here are 5 articles that give you a quick rundown of important matters for the pediatric provider.






